Xeris Biopharma Holdings, Inc. has announced impressive financial results for the third quarter of 2026, highlighting a significant growth trajectory for the company. The report, filed on November 5, 2026, reveals a 44% increase in total revenue year-over-year, reaching $107 million. This performance is particularly noteworthy as it reflects the company’s expanding market presence and product demand within the pharmaceutical preparations industry.

John Shannon, Chairman and CEO of Xeris, expressed optimism about the company's future, stating, "Our strong third quarter performance puts us on a new growth curve that is accelerating our Company’s near-term outlook, and we are now on a path to reach more than $1 billion in total revenue in 2030." The company also raised its full-year 2026 revenue guidance to between $395 million and $405 million, up from previous estimates.

Background

Xeris Biopharma Holdings, Inc., incorporated in Delaware, operates in the pharmaceutical preparations sector (SIC: 2834). The company trades on the Nasdaq under the ticker symbol XERS. Xeris focuses on developing and commercializing innovative medicines, particularly for endocrine and rare diseases. Recent filings include an 8-K on November 5, 2026, and several Form 4 filings on November 4, 2026.

What the Filing Says

The recent 8-K filing includes a press release detailing the company’s financial results and business highlights for the three and nine months ended September 30, 2026. Notably, net revenue from Recorlev, one of Xeris's key products, surged 93% year-over-year, contributing over $71 million to the total revenue. The company’s growth is attributed to a robust commercial strategy that has led to increased patient referrals and new starts.

Impact

This strong performance may positively affect various stakeholders, including investors, employees, and healthcare providers. Investors may view the increased revenue guidance as a sign of Xeris's solid market position and growth potential. Employees may benefit from job security and potential performance bonuses, while healthcare providers may gain access to more effective treatment options as Xeris expands its product offerings.

What's Next

The filing does not specify what happens next, but Xeris is expected to continue its momentum with upcoming product launches and clinical trials, including the initiation of a pivotal Phase 3 study for XP-8121 by year-end.